PT-141 (Bremelanotide) Complete Guide: Benefits, Dosing, Side Effects & Research

Introduction

PT-141, marketed as Vyleesi by Palatin Technologies, is the only melanocortin receptor agonist FDA-approved for a sexual dysfunction indication. The agency cleared it in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The mechanism has nothing to do with blood flow or testosterone. It works on the central nervous system, hitting melanocortin 4 receptors in the hypothalamus that gate sexual motivation.

The peptide started life as a sunless tanning agent called melanotan II. Researchers at the University of Arizona noticed that male volunteers in tanning trials reported spontaneous erections. That observation kicked off two decades of development, two phase 3 trials called RECONNECT, and an FDA approval that almost nobody uses because insurance rarely covers it.

This guide covers what PT-141 actually does, what the trials found, how Vyleesi is dosed compared with off-label compounded PT-141, side effects (the blood pressure issue is real), and where it fits if at all in a sexual health protocol.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is PT-141 and How Was It Developed?

PT-141 is bremelanotide, a synthetic cyclic heptapeptide derived from alpha-melanocyte stimulating hormone (alpha-MSH). The structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Palatin Technologies, a small New Jersey pharma company, developed it through the 2000s after the melanotan II observation about erections.

Quick Answer: PT-141 is a melanocortin 4 receptor agonist; bremelanotide (Vyleesi) is FDA-approved for premenopausal HSDD as of June 2019

The FDA approval covers premenopausal women with HSDD, not men with erectile dysfunction. Palatin tested PT-141 for ED earlier and abandoned that indication because of blood pressure concerns and the success of PDE5 inhibitors like sildenafil. The female sexual desire indication had no approved drug at the time apart from flibanserin (Addyi, approved 2015), and the FDA was under pressure to expand options.

Compounded PT-141 has become popular through wellness clinics and online providers. The compounded product uses the same molecule as Vyleesi but typically comes in multi-dose vials at variable concentrations. Quality control depends entirely on the source pharmacy, which is where 503A and 503B distinctions matter.

How Does PT-141 Work in the Brain?

PT-141 is a non-selective agonist at melanocortin receptors, with the strongest activity at MC4R, followed by MC1R and MC3R. The receptor relevant for sexual function is MC4R, expressed densely in the hypothalamic paraventricular nucleus and medial preoptic area. These regions are upstream of the sexual response. They generate the motivation and arousal signals that descend to autonomic and motor circuits.

When PT-141 binds MC4R, it activates a cascade that increases dopamine release in the medial preoptic area. Dopamine is the neurotransmitter most tightly linked to sexual motivation in animal models. So the drug effectively boosts a central pro-sexual signal without touching the vascular or hormonal system.

MC1R activation is what produces the skin darkening side effect that made tanning peptides popular. PT-141 hits MC1R less strongly than melanotan II, but multi-dose use can still cause focal hyperpigmentation, especially on the face.

What Did the RECONNECT Trials Show?

The RECONNECT trials were two identical phase 3 studies (Kingsberg et al. 2019 Obstet Gynecol) that enrolled 1,247 premenopausal women with acquired, generalized HSDD. Participants self-administered 1.75 mg bremelanotide subcutaneously on demand, no more than 8 times per month, for 24 weeks.

The primary endpoints were change in desire score (FSFI-D) and change in distress score (FSDS-DAO Item 13). Both improved on bremelanotide vs placebo. The desire score increase was 0.35 vs 0.21 (placebo). The distress score decrease was -0.74 vs -0.42. Statistically significant, modest in absolute terms.

The responder analysis is more useful. About 25% of treated women had a clinically meaningful response on desire (defined as a 1.2 point FSFI-D increase) vs 17% on placebo. The number needed to treat is about 12. That’s not a miracle drug, but it’s a real signal in a condition where almost nothing else works.

What About PT-141 for Men?

PT-141 is not FDA-approved for men. The original ED studies in the early 2000s found dose-related improvements in erectile function, but blood pressure increases were significant enough that Palatin pulled the program. There’s no completed phase 3 program for male erectile dysfunction.

Off-label compounded PT-141 use in men is common in wellness clinics. Anecdotal reports describe spontaneous erections and increased libido starting 1 to 2 hours after subcutaneous injection. The effect lasts several hours. The mechanism in men involves the same central dopamine pathway that operates in women, plus possibly direct effects on penile erection circuitry.

Without randomized trial data in men, dose selection is empirical. Most clinics start at 1 mg subcutaneously and titrate up. Side effects (nausea, flushing, blood pressure spike) are dose-related and roughly comparable to female trial data.

How Is PT-141 Dosed?

The FDA-approved Vyleesi dose is 1.75 mg subcutaneously into the abdomen or thigh, at least 45 minutes before anticipated sexual activity. The label limits use to 8 doses per 28 days and discourages dosing more than once in 24 hours. The package includes pre-filled autoinjectors.

Compounded PT-141 typically comes as a lyophilized powder reconstituted with bacteriostatic water. Concentrations vary from 1 mg/ml to 10 mg/ml. Standard doses range from 0.5 mg to 2 mg, with 1 to 1.75 mg being most common. Onset is 30 to 60 minutes, peak at 1 to 2 hours, duration 4 to 8 hours.

Higher doses don’t produce more sexual effect but do produce more side effects. The 1.75 mg ceiling in the Vyleesi label reflects the dose-response curve flattening out above that level for efficacy while side effects keep climbing.

Key Takeaway: Standard FDA dose is 1.75 mg subcutaneously, no more than 8 doses per month, at least 45 minutes before anticipated activity

What Side Effects Does PT-141 Cause?

Nausea is the dominant side effect. In RECONNECT, 40% of bremelanotide-treated women had nausea, vs 1% in placebo. About 8% had nausea severe enough to require antiemetic treatment, and 13% discontinued the drug because of it. Flushing affected 20%, injection site reactions 13%, and headache 11%.

Hyperpigmentation is the second concerning effect. About 1% of trial participants developed focal hyperpigmentation, usually on the face, gums, or breasts. The discoloration was reversible in most cases over weeks to months but not always. MC1R activation is the mechanism.

Blood pressure rises transiently after each dose. Mean increase is about 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after injection and resolving by 8 hours. Heart rate falls slightly. The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease.

Who Shouldn’t Use PT-141?

The Vyleesi label lists uncontrolled hypertension and known cardiovascular disease as contraindications. The pressor effect, while modest, adds cardiovascular risk in people already at risk. Anyone with a history of stroke, MI, or unstable angina should not use this drug.

Naltrexone use is another contraindication because PT-141 reduces naltrexone exposure by 60% and could compromise treatment for opioid use disorder. People taking domperidone or other dopamine antagonists may have reduced PT-141 effect.

Pregnancy is contraindicated. PT-141 has not been studied in pregnant women, and animal data suggest possible fetal effects. The label says women should avoid pregnancy during use and discontinue if pregnancy occurs.

Where Does PT-141 Fit Alongside Other Sexual Health Treatments?

For premenopausal women with HSDD, bremelanotide is one of two FDA-approved options. Flibanserin (Addyi) is the other. Flibanserin is a daily oral 5-HT1A agonist and 5-HT2A antagonist. The two drugs have similar efficacy in head-to-head comparisons of trial data (no actual head-to-head trial exists), but the dosing differs sharply. Flibanserin requires daily use and alcohol avoidance. PT-141 is on-demand and doesn’t interact with moderate alcohol.

For men, PDE5 inhibitors remain first-line for erectile dysfunction. PT-141 is a central drug that addresses motivation, not vascular function. Some men with low libido but adequate erectile function may benefit from PT-141, but the evidence is weaker than the evidence for testosterone replacement or psychological treatment.

The compounded PT-141 market is growing despite this evidence gap. Wellness clinics often pair PT-141 with other peptides like BPC-157 or with testosterone replacement. There’s no trial evidence supporting these stacks, only clinical experience and biological plausibility.

What Does TrimRx Think About PT-141?

PT-141 is a niche drug with real but modest effects. For premenopausal women with acquired HSDD, it’s one of very few options, and the trial data supports its approval. For men, the evidence is thinner and the side effect profile (especially blood pressure) deserves respect.

TrimRx focuses on GLP-1 medications for weight management. We’re not a sexual health clinic and we don’t prescribe PT-141. If sexual function is a concern alongside weight loss (and weight loss itself often improves sexual function), our medical team can suggest referral resources during the free assessment quiz.

Bottom line: Transient blood pressure increases (about 6 mmHg systolic) mean PT-141 is contraindicated in uncontrolled hypertension and cardiovascular disease

FAQ

How Long Does PT-141 Take to Work?

Subcutaneous PT-141 reaches peak plasma concentration about 1 hour after injection. Subjective effects on desire and arousal usually start 30 to 60 minutes after dosing and last 4 to 8 hours. The Vyleesi label suggests dosing 45 minutes before anticipated activity.

Can PT-141 Cause Permanent Skin Darkening?

PT-141 can cause focal hyperpigmentation through MC1R activation, especially with repeated use. In RECONNECT trials about 1% of women developed visible darkening, usually on the face. Most cases resolved over weeks to months after stopping the drug, but a few did not. Risk rises with cumulative dose.

Does PT-141 Work for Erectile Dysfunction?

PT-141 produces erections in men through central dopamine effects, but it’s not FDA-approved for ED. Palatin abandoned the ED program in the 2000s because of blood pressure concerns. Off-label use is widespread in wellness clinics but lacks phase 3 trial support. PDE5 inhibitors remain first-line for ED.

Is PT-141 the Same as Melanotan II?

PT-141 and melanotan II are structurally related but not identical. Both are alpha-MSH analogs that hit melanocortin receptors. Melanotan II hits MC1R more strongly, producing more skin darkening. PT-141 is more selective for MC4R, the sexual receptor. PT-141 was developed from melanotan II specifically to reduce the tanning effect.

How Much Does PT-141 Cost?

Vyleesi (FDA-approved bremelanotide) costs around $1,000 per month at retail for 4 autoinjectors. Insurance coverage is rare. Compounded PT-141 from 503A pharmacies typically runs $80 to $200 per month for a similar number of doses, but quality and concentration vary.

Can You Combine PT-141 with Viagra or Cialis?

Combining PT-141 with PDE5 inhibitors hasn’t been studied in trials. Both can affect blood pressure (PDE5 inhibitors lower it, PT-141 raises it briefly), so the combination could produce unpredictable hemodynamic effects. Anyone considering this combination should discuss it with a prescriber.

Is Compounded PT-141 Safe?

Compounded PT-141 from a properly licensed 503A pharmacy contains the same molecule as Vyleesi. Safety depends on the pharmacy’s quality controls, the prescriber’s evaluation, and patient screening for cardiovascular risk factors. The molecule itself has the same side effect profile regardless of source.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.